Patents by Inventor David K. Williams

David K. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoregulatory agents
    Patent number: 11932601
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Weiwei Guo
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11649212
    Abstract: The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: May 16, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weifang Shan, David K. Williams, Liping Zhang
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11447449
    Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, David K. Williams, Murugaiah Andappan Murugaiah Subbaiah
  • IMMUNOREGULATORY AGENTS
    Publication number: 20220274926
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: December 16, 2021
    Publication date: September 1, 2022
    Inventors: Hilary Plake BECK, Juan Carlos JAEN, Maksim OSIPOV, Jay Patrick POWERS, Maureen Kay REILLY, Hunter Paul SHUNATONA, James Ross WALKER, Mikhail ZIBINSKY, James Aaron BALOG, David K. WILLIAMS, Weiwei GUO
  • NLRP3 MODULATORS
    Publication number: 20220257587
    Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: April 28, 2022
    Publication date: August 18, 2022
    Inventors: Daniel O'Malley, Ashvinkumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • NLRP3 modulators
    Patent number: 11344543
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 31, 2022
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • NLRP3 MODULATORS
    Publication number: 20220089572
    Abstract: The present invention provides compounds of Formula (I):(I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Daniel O'MALLEY, Steven P. Seitz, Jay A. Markwalder, David K. Williams, Hua Gong, Scott Hunter Watterson, Christine M. Tarby
  • Immunoregulatory agents
    Patent number: 11242319
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 8, 2022
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Weiwei Guo
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210355113
    Abstract: The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Application
    Filed: July 20, 2019
    Publication date: November 18, 2021
    Inventors: James Aaron BALOG, Steven P. SEITZ, Jay A. MARKWALDER, David K. WILLIAMS, Weifang SHAN, Susheel Jethanand NARA, Saumya ROY, Srinivas CHERUKU, Nagalakshmi PULICHARLA
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210299126
    Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Application
    Filed: July 22, 2019
    Publication date: September 30, 2021
    Inventors: James Aaron BALOG, Jay A. MARKWALDER, Weifang SHAN, David K. WILLIAMS, Susheel Jethanand NARA, Saumya ROY, Soodamani THANGAVEL, Srinivas CHERUKU, Ramesh Kumar SISTLA
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11066392
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: July 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Liping Zhang, Audris Huang, Weifang Shan, David K. Williams, Xiao Zhu, Weiwei Guo
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11066383
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: David K. Williams, Weifang Shan, Liping Zhang, Emily Charlotte Cherney, James Aaron Balog
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210206723
    Abstract: The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Application
    Filed: October 8, 2018
    Publication date: July 8, 2021
    Inventors: James Aaron BALOG, Emily Charlotte CHERNEY, Weifang SHAN, David K. WILLIAMS, Liping ZHANG
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210070698
    Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.
    Type: Application
    Filed: January 3, 2019
    Publication date: March 11, 2021
    Inventors: James Aaron BALOG, Steven P. SEITZ, David K. WILLIAMS, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 10696648
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 30, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David K. Williams, Weifang Shan, James Aaron Balog
  • IDO inhibitors
    Patent number: 10689331
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: June 23, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Weifang Shan, David K. Williams
  • NLRP3 MODULATORS
    Publication number: 20200129500
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: July 12, 2018
    Publication date: April 30, 2020
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 10633342
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Weifang Shan, Liping Zhang, David K. Williams, Weiwei Guo, Audris Huang, James Aaron Balog
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20200095231
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 10, 2018
    Publication date: March 26, 2020
    Inventors: James Aaron BALOG, Emily Charlotte CHERNEY, Liping ZHANG, Audris HUANG, Weifang SHAN, David K. WILLIAMS, Xiao ZHU, Weiwei GUO
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 10544099
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Liping Zhang, David K. Williams, James Aaron Balog